119 related articles for article (PubMed ID: 16840889)
1. [Treatment of chronic lupus erythematosus with sulfasalazine in 18 patients: reappraisal].
Duparc A; Staumont-Sallé D; Broly F; Piette F; Delaporte E
Presse Med; 2006; 35(7-8):1138-42. PubMed ID: 16840889
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases].
Delaporte E; Catteau B; Sabbagh N; Gosselin P; Breuillard F; Doutre MS; Broly F; Piette F; Bergoend H
Ann Dermatol Venereol; 1997; 124(2):151-6. PubMed ID: 9740825
[TBL] [Abstract][Full Text] [Related]
3. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus.
Sabbagh N; Delaporte E; Marez D; Lo-Guidice JM; Piette F; Broly F
Pharmacogenetics; 1997 Apr; 7(2):131-5. PubMed ID: 9170150
[TBL] [Abstract][Full Text] [Related]
4. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
Ricart E; Taylor WR; Loftus EV; O'Kane D; Weinshilboum RM; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
Am J Gastroenterol; 2002 Jul; 97(7):1763-8. PubMed ID: 12135032
[TBL] [Abstract][Full Text] [Related]
5. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
Chen M; Xia B; Chen B; Guo Q; Li J; Ye M; Hu Z
Can J Gastroenterol; 2007 Mar; 21(3):155-8. PubMed ID: 17377643
[TBL] [Abstract][Full Text] [Related]
6. Sulfasalazine-induced lupus erythematosus.
Clementz GL; Dolin BJ
Am J Med; 1988 Mar; 84(3 Pt 1):535-8. PubMed ID: 2894766
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria.
Orden RA; Timble H; Saini SS
Ann Allergy Asthma Immunol; 2014 Jan; 112(1):64-70. PubMed ID: 24331396
[TBL] [Abstract][Full Text] [Related]
8. Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease.
Carr-Locke DL
Am J Gastroenterol; 1982 Sep; 77(9):614-6. PubMed ID: 6126117
[TBL] [Abstract][Full Text] [Related]
9. Fatal evolution of systemic lupus erythematosus associated with Crohn's disease.
Chebli JM; Gaburri PD; de Souza AF; Dias KV; Cimino KO; de Carvalho-Filho RJ; Lucca FA
Arq Gastroenterol; 2000; 37(4):224-6. PubMed ID: 11469224
[TBL] [Abstract][Full Text] [Related]
10. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.
Gunnarsson I; Kanerud L; Pettersson E; Lundberg I; Lindblad S; Ringertz B
Br J Rheumatol; 1997 Oct; 36(10):1089-94. PubMed ID: 9374926
[TBL] [Abstract][Full Text] [Related]
11. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
Dougados M; Emery P; Lemmel EM; Zerbini CA; Brin S; van Riel P
Ann Rheum Dis; 2005 Jan; 64(1):44-51. PubMed ID: 15271770
[TBL] [Abstract][Full Text] [Related]
12. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA.
Gunnarsson I; Nordmark B; Hassan Bakri A; Gröndal G; Larsson P; Forslid J; Klareskog L; Ringertz B
Rheumatology (Oxford); 2000 Aug; 39(8):886-93. PubMed ID: 10952745
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of patients with double stranded DNA antibodies induced by sulfasalazine during the treatment of inflammatory rheumatic diseases.
Mielke H; Wildhagen K; Mau W; Zeidler H
Scand J Rheumatol; 1993; 22(6):299-301. PubMed ID: 7903472
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.
Wadelius M; Stjernberg E; Wiholm BE; Rane A
Pharmacogenetics; 2000 Feb; 10(1):35-41. PubMed ID: 10739170
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene.
Tanaka E; Taniguchi A; Urano W; Nakajima H; Matsuda Y; Kitamura Y; Saito M; Yamanaka H; Saito T; Kamatani N
J Rheumatol; 2002 Dec; 29(12):2492-9. PubMed ID: 12465141
[TBL] [Abstract][Full Text] [Related]
16. Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.
Ohtani T; Hiroi A; Sakurane M; Furukawa F
Br J Dermatol; 2003 May; 148(5):1035-9. PubMed ID: 12786839
[TBL] [Abstract][Full Text] [Related]
17. [Sulfasalazine or interferon in the treatment of lupus: the hen, the egg and the wolf].
Piette JC; Frances C; Papo T; Godeau P
Presse Med; 1994 May; 23(20):956. PubMed ID: 7937641
[No Abstract] [Full Text] [Related]
18. Combination therapy for rheumatoid arthritis and drug-induced systemic lupus erythematosus.
Borg AA; Davis MJ; Dawes PT; Shadforth MF
Clin Rheumatol; 1994 Sep; 13(3):522-4. PubMed ID: 7835022
[TBL] [Abstract][Full Text] [Related]
19. Delayed pressure urticaria: response to treatment with sulfasalazine in a case series of seventeen patients.
Swerlick RA; Puar N
Dermatol Ther; 2015; 28(5):318-22. PubMed ID: 26134002
[TBL] [Abstract][Full Text] [Related]
20. Sulphasalazine-induced systemic lupus erythematosus in a patient with erosive arthritis.
Walker EM; Carty JE
Br J Rheumatol; 1994 Feb; 33(2):175-6. PubMed ID: 7909272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
